Injectable thermo-responsive nano-hydrogel loading triptolide for the anti-breast cancer enhancement via localized treatment based on “two strikes” effects

Yaoyao Luo,Jingjing Li,Yichen Hu,Fei Gao,George Pak-Heng Leung,Funeng Geng,Chaomei Fu,Jinming Zhang
DOI: https://doi.org/10.1016/j.apsb.2020.05.011
IF: 14.903
2020-11-01
Acta Pharmaceutica Sinica B
Abstract:<p>The clinical application of triptolide (TPL) in tumor therapy has been greatly limited by its toxicity and inefficient delivery. Herein, a localized and sustained-release thermo-sensitive hydrogel was developed for the intra-tumor administration of TPL. Based on the amphiphilic structure of poly (<em>N</em>-isopropylacrylamide<em>-co-</em>acrylic acid)-<em>g</em>-F68 copolymer, it was able to form nano-micelles to efficiently encapsulate TPL, and then turn into a hydrogel at 37 °C. exhibited a sustained drug release profile <em>in vitro</em> and a stronger anticancer effect caused by "two strikes". The "first strike" was its enhanced cytotoxicity compared to free TPL, due to the enhanced pro-apoptosis effect observed in both MDA-MB-231 and MCF-7 cells caused by the regulation of endogenous mitochondrial pathways. Furthermore, exhibited a "second-strike" through its anti-angiogenesis capabilities mediated through VEGFR-2 signaling inhibition. As expected, after intra-tumoral injection at a 0.45 mg/kg TPL-equivalent dose three times over 14 days in 4T1 tumor-bearing mice, led to lower systemic toxicity and higher antitumor efficacy compared to multiple injections of TPL. In this regard, these findings indicate that this injectable thermo-responsive hydrogel carries great potential for TPL as a safe and effective cancer therapy.</p>
pharmacology & pharmacy
What problem does this paper attempt to address?